share_log

Elevation Oncology Advances EO-3021 Trials to Target Advanced Gastric and GEJ Cancers With Improved Care

Elevation Oncology Advances EO-3021 Trials to Target Advanced Gastric and GEJ Cancers With Improved Care

愛文思控股推進EO-3021臨牀試驗,旨在改善晚期胃癌和胃食管交界癌患者的護理。
Benzinga ·  01/13 13:35

levation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones.

Elevation Oncology, Inc. (納斯達克:ELEV),是一家創新的腫瘤學公司,專注於發現和開發選擇性癌症治療方案,以滿足患有顯著未滿足的醫療需求的固體腫瘤患者,今天宣佈了項目更新和即將到來的里程碑。

"We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings. With our Phase 1 clinical trial ongoing and now enrolling both monotherapy and combination cohorts, we are in a leading position to explore the compelling potential of EO-3021, our differentiated Claudin 18.2 ADC, to improve outcomes for people living with advanced gastric/GEJ cancer."

Joseph Ferra,Elevation Oncology的總裁兼首席執行官表示:「我們正在迅速推進EO-3021,以應對在治療晚期胃/GEJ癌症早期療法中存在的顯著未滿足需求,我們相信自己在改善護理標準方面具有獨特的能力。隨着2025年的到來,我們將更加專注,利用EO-3021的競爭抗腫瘤活性和差異化的安全性來探索一線和二線設置中的聯合治療方案。隨着我們的I期臨牀試驗正在進行,現在正在招募單藥和聯合隊列,我們處於領先位置,以探索EO-3021的引人注目的潛力,我們與衆不同的Claudin 18.2 ADC,以改善晚期胃/GEJ癌症患者的治療效果。」

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。